Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CDA | P32320 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531921 | 1.00 | PYGL (0.39) | PYGLSLC5A2MAPTCDA | |
| SCHEMBL16710417 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL19101808 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL25008855 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL24982409 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL24982322 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL10154369 | 0.85 | HIF1A (0.46) | SLC5A2 | |
| SCHEMBL14942978 | 0.84 | ADK (0.42) | SLC5A2 | |
| SCHEMBL18571929 | 0.84 | SLC5A2 (0.38) | SLC5A2 | |
| SCHEMBL23959991 | 0.83 | ADK (0.39) | PYGLSLC5A2MAPTCDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | PYGL 1274/4885SLC5A2 1545/4885MAPT 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.